The proprietary Multi Affilin® platform allows multimerization of Affilin® therapeutics, generatingadjustable serum half-lifes from minutes to days
Scil Proteins owns a patented multimerization technology for Affilin® molecules. This technique allows the modulation of affinity and pharmacokinetics. Different multimerization strategies are available:
Multimerization of Affilin® monomers to Affilin® tetramers: Affinity optimization by the factor of up to 1.000 and/or serum halflife prolongation from minutes to hours.
Multimerization of Affilin® dimers to Affilin® octamers: Affinity optimization by the factor of several hundreds and/or serum half-life prolongation up to days.
